Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA
19 1월 2023 - 7:00PM
Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and
diagnostic testing, today announced an executive leadership change
to ensure the company realizes the full potential of its broad
genetics and digital testing platform and as a commitment to the
EMEA market. To be effective immediately, Dr. Bayju Thakar is
appointed as CEO and shall join the board of directors for
Prenetics EMEA Limited (“Prenetics EMEA”), a wholly owned
subsidiary of Prenetics Global Limited.
“Prenetics has strong ambitions in the UK and EMEA markets. They
are highly complex healthcare markets, which require very specific
domain expertise and networks to thrive. Bayju understands the
healthcare system dynamics incredibly well and is the ideal leader
to significantly grow our EMEA business, creating value for all
stakeholders. I am delighted to welcome Bayju Thakar as CEO of
Prenetics EMEA. Bayju’s vast digital health, medical, and operating
experience as co-founder and ex-CEO of Doctor Care Anywhere, UK’s
largest telehealth primary care business with more than 2 million
lives, will help Prenetics Global build a leading modern health
ecosystem in EMEA and globally,” said Danny Yeung, Chief Executive
Officer of Prenetics Global Limited.
Dr. Bayju Thakar, Chief Executive Officer, EMEA said “I am
honored to take on the EMEA CEO role and lead Prenetics forward at
this important inflection point. I look forward in partnering with
Danny to build upon our strong foundation and further position
Prenetics as a leader in healthcare. The expertise of our team and
Prenetics’ strong balance sheet will enable us to pursue both
organic and inorganic growth across a number of major healthcare
opportunities, including primary and secondary care clinical
services, IVF / fertility, and personalized cancer
diagnostics.”
Dr. Bayju Thakar Biography
Dr. Thakar has more than 20 years of healthcare and digital
health, M&A, strategic partnerships and board experience. Most
recently, Dr. Thakar served as Co-Founder and former CEO of Doctor
Care Anywhere Group PLC, UK’s largest telehealth primary care
business with more than 2 million lives under coverage. Dr. Thakar
trained as a medical doctor at King's College, London, and then
practised in both General and Emergency medicine before a move to
consulting at McKinsey & Company.
About Prenetics
Founded in 2014, Prenetics is a leading global diagnostic and
genetic testing company with the mission to bring health closer to
millions of people globally by making the three pillars — Consumer
Health, Clinical Care and Medical & Cancer Genomics -
comprehensive and accessible to anyone. Prenetics has operations
across nine locations, including The United Kingdom, Hong Kong,
India, South Africa, and Southeast Asia. Prenetics is listed on
NASDAQ with the ticker PRE. To learn more about Prenetics,
visit www.prenetics.com.
Investor Relations
Contact:investors@prenetics.com
ICR
Westwicke: |
|
|
Caroline Corner |
+415 202 5678 |
Email:
caroline.corner@westwicke.com |
|
|
|
Media
contact: |
|
|
Strategic Public
Relations Group |
|
|
Corinne Ho |
+852 2114 4911 |
Email:
corinne.ho@sprg.com.hk |
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. In some cases, you can identify forward-looking statements by
terminology such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “should,” “plan,” “expect,”
“predict,” “potential,” or the negative of these terms of other
similar expressions. Forward-looking statements are based on
Prenetics’ expectations and assumptions as of the date of this
press release and are subject to inherent uncertainties, risks and
changes in circumstances that may differ materially from those
contemplated by the forward-looking statements. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including but
not limited to: Prenetics’ ability to execute its strategies,
manage growth and maintain its corporate culture as it grows; the
regulatory environment and changes in laws, regulations, or
policies in which Prenetics operates; Prenetics’ ability to
successfully compete in highly competitive industries and markets;
Prenetics’ ability to continue to adjust its offerings to meet
market demand; Prenetics ability to attract customers to choose its
products and services and grow its ecosystem; political instability
in the jurisdictions in which Prenetics operates; and the overall
economic environment and general market and economic conditions in
the jurisdictions in which Prenetics operates. In addition to the
foregoing factors, you should also carefully consider the other
risks and uncertainties included in Prenetics’ filings with the
U.S. Securities and Exchange Commission (the “SEC”) from time to
time.
Forward-looking statements speak only as of the date they are
made. Prenetics does not undertake any obligation to update any
forward-looking statement, whether as a result of new information,
future developments, or otherwise, except as required under
applicable law.
Prenetics Global (NASDAQ:PRE)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Prenetics Global (NASDAQ:PRE)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024